in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Lonza: Improvement in Custom Manufacturing Business but Volatility Remains
April 22, 2010 | Deepti Ramesh
Lonza, in its business update announcement for the first quarter of 2010, says that the company’s custom manufacturing business signed several new contracts in the first quarter, and the life science ingredients business had a strong performance. The visibility is improving in all businesses, but volatility still persists in the custom manufacturing business, Lonza says. “Although the environment remains volatile and we do not trust the stronger demand to represent true and full economic recovery, the progress in the first quarter is...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee